InMed Pharmaceuticals

INM

Market cap $3.67M

Data demonstrate a favorable bioavailability profile of INM-901 oral formulation Data will support design and planning of first in human clinical trials Preparing for pre-IND meeting with the FDA Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today announced the successful completion of pharmacokinetic ("PK") studies in large animal models for its Alzheimer's disease candidate INM-901. This marks the first preclinical study in which the oral formulation of INM-901 was administered in large animals.

Vancouver, British Columbia--(Newsfile Corp. - November 6, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its first quarter of fiscal year 2026, which ended September 30, 2025. The Company's full financial statements and related MD&A for the first quarter ended September 30, 2025, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.

Vancouver, British Columbia--(Newsfile Corp. - October 16, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. John Bathery to its Board of Directors, effective immediately.

Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. Neil Klompas, CPA, CA to its Board of Directors, effective immediately.

Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathology Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration Cash of $11.1M to support pharmaceutical developments into the fourth quarter of calendar year 2026 Vancouver, British Columbia--(Newsfile Corp. - September 23, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced financial results for its fiscal year ending June 30, 2025 and provided a business update on its pharmaceutical drug development programs as well as the commercial segment for its wholly-owned subsidiary, BayMedica, LLC ("BayMedica"). The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2025, are available at www.inmedpharma.com and at www.sedar.com.

VANCOUVER, British Columbia, Sept. 16, 2025 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that Eric A. Adams, InMed's CEO, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 18th, 2025.

Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that the Company will be participating in the H.C. Wainwright 27th Annual Global Investment Conference in New York.

Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activity Vancouver, British Columbia--(Newsfile Corp. - July 28, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it is presenting new preclinical data from its INM-901 program at the upcoming Alzheimer's Association International Conference (AAIC) 2025, the world's leading forum for Alzheimer's disease ("AD") and dementia research. Data will be presented in a scientific poster entitled, " Therapeutic Potential of INM-901 in Mitigating Alzheimer's Disease Pathology: Insights from a Long-term 5xFAD Mouse Model Study ".

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof) and associated short-term preferred investment option. The short-term preferred investment option issued in the offering is exercisable immediately upon issuance at an exercise price of $2.436 per share and will expire eighteen months from the effective date of the Resale Registration Statement (as defined below).

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof) and associated short-term preferred investment option in a private placement priced at-the-market under Nasdaq rules. The short-term preferred investment option to be issued in the offering will be exercisable immediately upon issuance at an exercise price of $2.436 per share and will expire eighteen months from the effective date of the Resale Registration Statement (as defined below).